Loading
A phase 1/2 trial of Temozolomide in glioma & glioblastoma, run by Hangzhou Hanx Biopharmaceuticals, Ltd., now recruiting.
A Phase 2 Study of HX301 in Patients with High-grade Giloma is a phase 1/2 interventional study registered as NCT06703255 by Hangzhou Hanx Biopharmaceuticals, Ltd., with 72 participants planned, started 2025-01-08 and due to reach its primary completion in 2026-12-31. Interventions recorded: HX301+/Temozolomide.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Shares Hangzhou Hanx Biopharmaceuticals and the tag pipeline.
Shares Temozolomide, Glioma & glioblastoma, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/